Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sEphB4-HSA + chemotherapy
- Development stage
- Unknown
- Lead developer
- Vasgene Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
sEphB4-HSA + chemotherapy is a combination therapy consisting of the recombinant fusion protein sEphB4-HSA and standard chemotherapeutic agents. sEphB4-HSA is an albumin-bound extracellular fragment of the EphB4 receptor, designed to inhibit the interaction between EphB4 and its ligand, EphrinB2. This blockade disrupts bidirectional signaling that promotes tumor angiogenesis, growth, and immune evasion. By inhibiting this pathway, sEphB4-HSA suppresses downstream oncogenic signals (such as KRAS and PI3K) and enhances immune cell infiltration into tumors. When combined with standard chemotherapies like cisplatin or carboplatin (for various cancers including pancreatic cancer [PC] and bladder cancer [BC]), this regimen aims to improve disease control by targeting both tumor cell proliferation (via chemotherapy) and tumor microenvironment/angiogenesis (via sEphB4-HSA)[1][4]. The combination has been studied in phase Ib/II trials for advanced solid tumors.
- Other names
- soluble EphB4-human serum albumin fusion protein + chemotherapy
02
Targets
EFNB2 (Ephrin-B2)
Beyond the preview
Go deeper on sEphB4-HSA + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sEphB4-HSA + chemotherapy.